Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies

被引：0

作者：

Ishida, Tadao ^{[1
]}

Yokoyama, Hisayuki ^{[2
]}

Suzuki, Kenshi ^{[1
]}

Ito, Satoshi ^{[3
]}

Nagai, Yuya ^{[4
]}

Handa, Hiroshi ^{[5
]}

Ito, Shigeki ^{[6
]}

Kamei, Yoichi ^{[7
]}

Nakamura, Masatoshi ^{[7
]}

Viqueira, Andrea ^{[8
]}

White, Jane Liang ^{[9
]}

Take, Kazumi ^{[9
]}

Moribe, Toyoki ^{[10
]}

Iida, Shinsuke ^{[11
]}

机构：

[1] Japanese Red Cross Med Ctr, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Yamagata Univ Hosp, Yamagata, Japan

[4] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan

[5] Gunma Univ, Grad Sch Med, Maebashi, Gumma, Japan

[6] Iwate Med Univ, Sch Med, Yahaba, Iwate, Japan

[7] Pfizer R&D Japan GK, Tokyo, Japan

[8] Pfizer SLU, Madrid, Spain

[9] Pfizer Inc, Groton, CT USA

[10] Pfizer Japan Inc, Tokyo, Japan

[11] Nagoya City Univ, Inst Med & Pharmaceut Sci, Nagoya, Aichi, Japan

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-274

引用

页码：S186 / S187

页数：2

共 50 条

[21] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
Grosicki, Sebastian
Mellqvist, Ulf-Henrik
Pruchniewski, Lukasz
Crafoord, Jacob
Trudel, Suzanne
Min, Chang-Ki
White, Darrell
Alegre, Adrian
Hansson, Markus
Ikeda, Takashi
Sunami, Kazutaka
Leip, Eric
Kudla, Arthur
Finn, Gregory
Koh, Youngil
BLOOD, 2022, 140 : 4407 - 4408
[22] Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Bahlis, Nizar J.
Costello, Caitlin L.
Raje, Noopur S.
Levy, Moshe Y.
Dholaria, Bhagirathbhai
Solh, Melhem
Tomasson, Michael H.
Damore, Michael A.
Jiang, Sibo
Basu, Cynthia
Skoura, Athanasia
Chan, Edward M.
Trudel, Suzanne
Jakubowiak, Andrzej
Gasparetto, Cristina
Chu, Michael P.
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
NATURE MEDICINE, 2023,
[23] MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
Prince, H. Miles
Bahlis, Nizar J.
Rodriguez-Otero, Paula
Karlin, Lionel
Akard, Luke
Varshavsky-Yanovsky, Asya
Chu, Michael P.
Nagai, Yuya
Vesole, David H.
Hickman, Anne
Sullivan, Sharon T.
Leip, Eric
Conte, Umberto
Viqueira, Andrea
Lesokhin, Alexander M.
BLOOD, 2024, 144 : 4738 - 4739
[24] Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
Tomasson, Michael H.
Iida, Shinsuke
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Martinez-Lopez, Joaquin
Koehne, Guenther
Rodriguez-Otero, Paula
Prince, H. Miles
Viqueira, Andrea
Leip, Eric
Conte, Umberto
Sullivan, Sharon T.
Lesokhin, Alexander M.
HEMASPHERE, 2024, 8 (07):
[25] Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Bahlis, Nizar J.
Costello, Caitlin L.
Raje, Noopur S.
Levy, Moshe Y.
Dholaria, Bhagirathbhai
Solh, Melhem
Tomasson, Michael H.
Damore, Michael A.
Jiang, Sibo
Basu, Cynthia
Skoura, Athanasia
Chan, Edward M.
Trudel, Suzanne
Jakubowiak, Andrzej
Gasparetto, Cristina
Chu, Michael P.
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
NATURE MEDICINE, 2023, 29 (10) : 2570 - +
[26] Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Nizar J. Bahlis
Caitlin L. Costello
Noopur S. Raje
Moshe Y. Levy
Bhagirathbhai Dholaria
Melhem Solh
Michael H. Tomasson
Michael A. Damore
Sibo Jiang
Cynthia Basu
Athanasia Skoura
Edward M. Chan
Suzanne Trudel
Andrzej Jakubowiak
Cristina Gasparetto
Michael P. Chu
Andrew Dalovisio
Michael Sebag
Alexander M. Lesokhin
Nature Medicine, 2023, 29 : 2570 - 2576
[27] Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
Tomasson, Michael H.
Bahlis, Nizar J.
Costello, Caitlin
Raje, Noopur S.
Levy, Moshe Y.
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Damore, Michael A.
Jiang, Sibo
Xie, Tao
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Gasparetto, Cristina
Chu, Michael
Dalovisio, Andrew Peter
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Berenson, James R.
Silagan, Noemi
To, Jennifer
Spektor, Tanya M.
Martinez, Daisy
Sanchez, Armando J.
Forouzan, Eli
Swift, Regina
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Boccia, Ralph V.
Yang, Honghao Hank
Lim, Stephen
Vescio, Robert
BLOOD, 2020, 136
[29] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin
Michael H. Tomasson
Bertrand Arnulf
Nizar J. Bahlis
H. Miles Prince
Ruben Niesvizky
Paula Rodrίguez-Otero
Joaquin Martinez-Lopez
Guenther Koehne
Cyrille Touzeau
Yogesh Jethava
Hang Quach
Julien Depaus
Hisayuki Yokoyama
Afshin Eli Gabayan
Don A. Stevens
Ajay K. Nooka
Salomon Manier
Noopur Raje
Shinsuke Iida
Marc-Steffen Raab
Emma Searle
Eric Leip
Sharon T. Sullivan
Umberto Conte
Mohamed Elmeliegy
Akos Czibere
Andrea Viqueira
Mohamad Mohty
Nature Medicine, 2023, 29 : 2259 - 2267
[30] Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3
Touzeau, Cyrille
Weisel, Katja
Bahlis, Nizar
Quach, Hang
Hamilton, Finn
Wang, Shen-wu
Leip, Eric
Viqueira, Andrea
O'Brien, Thomas
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S82 - S83

← 1 2 3 4 5 →